Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.40 |
| ▸ | PDE2A | O00408 | 4/20 | 0.36 |
| ▸ | BTK | Q06187 | 5/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8954979 | 0.82 | PDE4B (0.38) | PDE4BPDE2ABTKKCNH2 | |
| SCHEMBL8994812 | 0.77 | CYP3A4 (0.41) | PDE4B | |
| SCHEMBL13006565 | 0.74 | KCNH2 (0.41) | KCNH2 | |
| SCHEMBL9006694 | 0.73 | QDPR (0.36) | — | |
| SCHEMBL23107999 | 0.72 | ESR2 (0.33) | KCNH2 | |
| SCHEMBL23108006 | 0.72 | ESR2 (0.33) | KCNH2 | |
| SCHEMBL15215227 | 0.68 | GSK3B (0.31) | — | |
| SCHEMBL14413518 | 0.67 | HSD11B1 (0.56) | PDE4BHSD11B1SPRSCD | |
| SCHEMBL29640084 | 0.67 | HSD11B1 (0.59) | HSD11B1SPR | |
| SCHEMBL2044316 | 0.67 | AOC3 (0.43) | PDE4BHSD11B1SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188085-B2 | Antifungal agents | MERCK SHARP & DOHME CORP. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100113439-A1 | Antifungal agents | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113439-A1 | Antifungal agents | GMDS, GBA3, UGGT1 | PDE4B 671/4885PDE2A 422/4885BTK 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.